- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07562217
Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis (LIAISE Study) (LIAISE)
Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis: a Prospective Observational Study (LIAISE Study)
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Background Sepsis is a global killer, whereby an infection spreads throughout the body via the bloodstream. It often leads to lethal heart damage, "septic cardiomyopathy", with mortality rates for those affected soaring above 40%. To facilitate early and appropriate intervention for damaged hearts and improve their outcomes, accurate assessment of heart function, and proper prediction of their adverse events are crucial. However, conventional cardiac assessments cannot capture heart dysfunction accurately since they have a significant limitation called "load-dependency", which means these parameters' values are affected by loading conditions on the heart, such as blood pressure and circulating blood volume. In sepsis, as these loads on the heart dramatically change minute by minute, the values of cardiac assessment also fluctuate and frequently underestimates heart damage, failing to properly predict their adverse events. To address this, novel load-incorporating echocardiographic parameters can capture heart function more accurately regardless of these hemodynamic conditions, and previous data has demonstrated its better predictive value in cardiogenic shock cases where loading conditions similarly fluctuate. As a next step, this study seeks to elucidate their utility in patients with sepsis.
Aims
- To investigate if novel load-incorporating echocardiography can predict adverse events more accurately than conventional parameters in adult patients with sepsis presenting to intensive care units (ICUs).
- To identify the most sensitive cardiac parameter to predict adverse events in sepsis, from comprehensively collected cardiac parameters along with novel-incorporating echocardiography.
Hypothesis Load-incorporating echocardiographic parameters will be more accurate in predicting the incidence of adverse events within 30 days after ICU admission than conventional echocardiographic parameters.
Outcomes Primary outcome The incidence of all-cause death for 30 days after ICU admission
Secondary outcomes
- Incidence of and time to all-cause death or cardiovascular readmission for 1 year after ICU admission
- Incidence and duration of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission.
- Reversibility of cardiac function (LVEF increases ≥ 5% in echo 3-5 days after ICU admission)
- Sequential Organ Failure Assessment (SOFA) score at 3 days after ICU admission
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Hideaki Nonaka, Dr
- Telefoonnummer: +61 449967910
- E-mail: hideaki54nonaka@gmail.com
Studie Contact Back-up
- Naam: Nonaka
Studie Locaties
-
-
Queensland
-
Chermside, Queensland, Australië, 4032
- The Prince Charles Hospital
-
Contact:
- Hideaki Nonaka, Dr
- Telefoonnummer: +61 449967910
- E-mail: hideaki54nonaka@gmail.com
-
Contact:
- Nonaka
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Adults ≥ 18 years old.
- Clinically suspected of defined sepsis
- Sepsis-induced hypotension or hypoperfusion (arterial or venous blood lactate ≥2.0 mmol/L OR mean artery pressure ≤65 mmHg over 30 mins OR at least one vasoactive or inotropic agent administered).
- At least one dose of an IV antimicrobial has been commenced.
Exclusion Criteria:
- Suspected or confirmed pregnancy.
- Any severe concomitant diseases with limited life expectancy <30 days.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Sepsis with hypotension or signs of hypoperfusion admitted to ICU
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
All cause death
Tijdsspanne: Day 30 after ICU admission
|
Day 30 after ICU admission
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
All cause death and adverse cardiac event readmission
Tijdsspanne: 1 year after ICU admission
|
Incidence of and time to all-cause death or adverse cardiac event readmissions for 1 year after ICU admission
|
1 year after ICU admission
|
|
Mechanical circulartory suport, mechanical ventilation, renal replacement therapy, and vasoactive/inotropic agent therapy
Tijdsspanne: during the initial index admission, between Day 0 and Day 30
|
Incidence and duration (days) of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission
|
during the initial index admission, between Day 0 and Day 30
|
|
Reversibility of cardiac function
Tijdsspanne: Day 3 to Day 5
|
Left ventricular ejection fraction increases ≥ 5% in echo from 3-5 days after ICU admission
|
Day 3 to Day 5
|
|
Sequential Organ Failure Assessment score at 3 days after ICU admission
Tijdsspanne: at Day 3 of ICU admission
|
Sequential Organ Failure Assessment score at Day 3 of index ICU admission will be assessed on a scale from 0 to 24, with higher scores indicating more severe organ failure.
|
at Day 3 of ICU admission
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
lengh of hosiptal or ICU stay
Tijdsspanne: during the initial index admission, between Day 0 and Day 30
|
during the initial index admission, between Day 0 and Day 30
|
|
|
In-hospital mortariy
Tijdsspanne: during the initial index admission, between Day 0 and Day 30
|
during the initial index admission, between Day 0 and Day 30
|
|
|
Vasoactive-inotropic score at 24, and 48 hours
Tijdsspanne: at 24 hour and 48 hour of index ICU admission
|
at 24 hour and 48 hour of index ICU admission
|
|
|
Amount of fluid administered for the first 24 hours in ICU admission
Tijdsspanne: Day 1 of index ICU admission
|
CSL
|
Day 1 of index ICU admission
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Hideaki Nonaka, Dr, The University of Queensland
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2025/PR011848
- INN2024-16 (Ander subsidie-/financieringsnummer: The Prince Charles Hospital Foundation (The Common Good))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .